ライフサイエンスコーパス: cannabinoid

1 es have evaluated the therapeutic effects of cannabinoids.

2 e snapshots of the molecular pharmacology of cannabinoids.

3 is chemotypes divergent for alkyl and cyclic cannabinoids.

4 erpenoids, monoterpene indole alkaloids, and cannabinoids.

5 rstand how basal ganglia (BG) is affected by cannabinoids.

6 al disorders might therefore be treated with cannabinoids.

7 Cannabinoid 1 receptor (CB1R) allosteric ligands hold a

8 t is unclear if WM deficits may be linked to cannabinoid 1 receptor dysfunction in schizophrenia.

9 Muscle cannabinoid 1 receptor regulates Il-6 and myostatin expr

10 olescence resulted in the down-regulation of cannabinoid 1 receptors (CB(1)Rs) in adulthood in a sex

11 induced bone formation in the femur via the cannabinoid-1 (CB1) receptor.

12 mote energy conservation in obesity, whereas cannabinoid-1 receptor (CB(1) R) blockade reverses body

13 Activation of the cannabinoid-1 receptor (CB1R) and activation of inducibl

14 Activating the renal cannabinoid-1 receptor (CB1R) induces nephropathy, where

15 Cannabinoid-1 receptors (CB1Rs) largely mediate the cent

16 ncipal biosynthetic enzyme of the endogenous cannabinoid 2-arachidonylglycerol (2-AG) on neurons, pla

17 Treatment of mice with a selective cannabinoid-2 receptor (CB(2) -R) agonist, known to atte

18 ndances of nearly all of the dozens of known cannabinoids(4), and their structural complexity, which

19 The first total synthesis of potent cannabinoid, 9beta-11-hydroxyhexahydrocannabinol, is ach

20 soprenylated resorcinyl polyketides known as cannabinoids, a subset of which are medically important

21 These findings encourage the study of cannabinoids acting on CB1 receptors in chronic gastroin

22 In mammals, cannabinoids activate two canonical receptors, CB(1)/CB(

23 this study, we evaluated whether (synthetic) cannabinoid activity can be detected in oral fluid (OF)

24 compounds, makes understanding how exogenous cannabinoids affect brain development an important biome

25 taling 32 mus, with and without bound potent cannabinoid agonist CP-55940.

26 f the nutraceutically important amino acids, cannabinoids, alkaloids, and fatty acids, the high altit

27 The cannabinoid alkyl group is a critical structural feature

28 terminants underlying in planta variation of cannabinoid alkyl side-chain length remain uncharacteris

29 The cannabinoid alkyl side-chain represents an important pha

30 A first-in-class cannabinoid analog called lenabasum that is a CB2 agonis

31 atty acids to our engineered strains yielded cannabinoid analogues with modifications in the part of

32 miscuity of several pathway genes to produce cannabinoid analogues.

33 tion to raising concerns about the safety of cannabinoid and alcohol exposure during early embryonic

34 ) in complex with an "ultrapotent" synthetic cannabinoid and its G protein (Krishna Kumar et al., 201

35 as an unprecedented mechanistic link between cannabinoids and motor performance, and suggest that act

36 onstrates that mice voluntarily consume both cannabinoids and opioids via gelatin, and that cannabino

37 exists that several drug classes, including cannabinoids and SSRIs, are ineffective.

38 jor components of the cannabis resin are the cannabinoids and terpenes.

39 f genes involved in the biosynthesis of both cannabinoids and terpenoids from imported precursors.

40 Cannabinoids and terpenoids were quantified in flower bu

41 e biosynthesis and storage of resins rich in cannabinoids and terpenoids.

42 ns arising from use of adulterated synthetic cannabinoids and their management.

43 acterize the plasma pharmacokinetics (PK) of cannabinoids and their metabolites in cattle after a sin

44 luding medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as te

45 vercome pharmacokinetic challenges with oral cannabinoids, and to uncover the exact mechanisms by whi

46 Cannabinoids are notorious and profound modulators of be

47 The U.S. FDA recently approved one cannabinoid-based drug whose active pharmaceutical ingre

48 al studies show that 'medicinal' cannabis or cannabinoid-based medications relieve pain in human dise

49 ough progress has been made in understanding cannabinoid binding and receptor activation, detailed kn

50 hemp variety "Finola." The map reveals that cannabinoid biosynthesis genes are generally unlinked bu

51 models, and tandem arrays of isoprenoid and cannabinoid biosynthetic genes.

52 oelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with G(i), as w

53 bolism) counteracts the rewarding effects of cannabinoids by acting as a negative allosteric modulato

54 or recreational and medical use of exogenous cannabinoids by pregnant and breastfeeding women.

55 Cannabinoids can alleviate chemotherapy-induced nausea a

56 neurobiological evidence demonstrating that cannabinoids can also alter the brain's initial molecula

57 eport the complete biosynthesis of the major cannabinoids cannabigerolic acid, Delta(9)-tetrahydrocan

58 ), a psychoactive constituent that activates cannabinoid CB(1) and CB(2) receptors.

59 The cannabinoid CB(1) receptor localizes to the glutamatergi

60 gy-modulating strategies in vivo showed that cannabinoid CB(1) receptors located on neurons belonging

61 Cannabinoid CB(2) receptor (CB(2)) agonists are potentia

62 The recombinant cannabinoid CB(2) receptor was expressed at high yield i

63 their synthetic and degradative enzymes, and cannabinoid (CB) receptors.

64 oylglycerol (2-AG), a potent agonist at both cannabinoid CB1 and CB2 receptors.

65 f endocannabinoids that activate presynaptic cannabinoid CB1 receptors on juxtaposing axon terminals.

66 Type 1 cannabinoid (CB1 ) receptors are widely distributed in t

67 Endocannabinoid activation of cannabinoid (CB1) receptors known to inhibit presynaptic

68 The cannabinoids CBDA, tetrahydrocannabinolic acid-A (THCA-A

69 We tested whether cannabinoids (CBs) potentiate alcohol-induced birth defe

70 ong to the phenylethylamine, tryptamine, and cannabinoid chemical classes for treating mental health

71 govern dicyclic (CBDA) and tricyclic (THCA) cannabinoid composition.

72 er previously identified peripherally active cannabinoid compounds, and could have clinical applicati

73 Plasma cannabinoid concentrations were profiled using liquid ch

74 s tightly linked to a known marker for total cannabinoid content.

75 ics, including the molecular determinants of cannabinoid content.

76 species (C. indica and C. sativa), and major cannabinoid contents (tetrahydrocannabinol, THC; and can

77 We tested whether cannabinoids could be detected on surfaces and objects i

78 The cannabinoid Delta(9)-tetrahydrocannabinol (THC) disrupts

79 Under on-chip exposure to the psychoactive cannabinoid, Delta-9-tetrahydrocannabinol (THC), cerebra

80 2-AG or AEA activate NPR-19 directly and cannabinoid-dependent inhibition can be rescued in npr-1

81 dulation of monoaminergic signaling, and the cannabinoid-dependent modulation of behavior.

82 ependent signaling pathway that involves the cannabinoid-dependent release of both serotonin and dopa

83 talytic activity, providing insight into how cannabinoid diversity arises in cannabis.

84 buspirone does not improve outcomes and that cannabinoids do not increase abstinence rates (moderate

85 Delta(9)-tetrahydrocannabinol or a synthetic cannabinoid during the first 10 days of postnatal develo

86 Treating rat dams with cannabinoids during early lactation retards transcriptio

87 ther, pharmacologically enhancing endogenous cannabinoids (eCB) with JZL184 prevents abstinence-induc

88 ns further reveal that cholesterol regulates cannabinoid enhancement of GlyR function through both di

89 These results show acidic cannabinoids, especially CBDA, are readily absorbed from

90 ndrome have had recent exposure to synthetic cannabinoids, evidence of isolated vitamin K antagonism

91 otential therapeutic tools to treat specific cannabinoid-evoked behavioral alterations.

92 annabidiol or other exogenous and endogenous cannabinoids exert their therapeutic effects.

93 Cannabinoids exert therapeutic effects on several diseas

94 misregulation in animal models of perinatal cannabinoid exposure (using synthetic cannabinoids or ac

95 preclinical data demonstrate that adolescent cannabinoid exposure reprograms the initial behavioral,

96 These results reveal how perinatal cannabinoid exposure retards an early milestone of devel

97 ng at >1400 sites in neurons after prolonged cannabinoid exposure.

98 bupropion for substance abuse disorders, and cannabinoids for epilepsy.

99 rise evidence regarding the effectiveness of cannabinoids for medicinal use and describe approaches t

100 ing interest in the therapeutic potential of cannabinoids for neurological disorders such as epilepsy

101 The safety of medicinal cannabinoids for these mental disorders was also examine

102 t evidence to provide guidance on the use of cannabinoids for treating mental disorders within a regu

103 Certain cannabinoid formulations have been approved as prescript

104 The recovery of cannabinoids from plant material was >93%.

105 suggest that cholesterol is critical for the cannabinoid-GlyR interaction in the cell membrane.

106 ever, whether membrane cholesterol regulates cannabinoid-GlyR interaction remains unknown.

107 alysis, and that the interpretative value of cannabinoid hair measurements from people reporting appl

108 f pain, but long-term treatment of pain with cannabinoids has been challenging to implement in precli

109 tream smoke/vapor and secondhand exposure to cannabinoids has been described in the literature.

110 However, the study and medicinal use of cannabinoids has been hampered by the legal scheduling o

111 Although more than 100 different cannabinoids have been isolated from Cannabis plants, cl

112 Synthetic cannabinoids have been linked to more sustained and dele

113 Cannabinoids have surely been one of the most widely sel

114 inhaled cannabis were more likely to be for cannabinoid hyperemesis syndrome (18.0% vs. 8.4%), and v

115 Side effects such as cannabinoid hyperemesis syndrome affect some users.

116 Marijuana smoke contains cannabinoids, immunosuppressants, and a mixture of poten

117 There is scarce evidence to suggest that cannabinoids improve depressive disorders and symptoms,

118 ning any type and formulation of a medicinal cannabinoid in adults (>=18 years) for treating depressi

119 Then, it was applied to determine the cannabinoids in 78 food, 16 beverage and 6 feed samples,

120 ural findings from experimental studies with cannabinoids in animals, and studies of hippocampal macr

121 To this aim, nine cannabinoids in beverages and food for human consumption

122 t of Delta(9)-tetrahydrocannabinol and other cannabinoids in food and feed derived from hemp and in f

123 hieving identification and quantification of cannabinoids in food matrices.

124 In this study, the occurrence of cannabinoids in hemp-based food products was investigate

125 However, intestinal lymphatic transport of cannabinoids in immunocompromised patients requires caut

126 However, small clinical trials of cannabinoids in other neurological disorders such as Hun

127 aman-based quantitative diagnostics of these cannabinoids in plant material.

128 The amount of cannabinoids in the plant material can be determined usi

129 iveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental diso

130 transport protein and a critical mediator of cannabinoid inactivation.

131 Medicinal cannabinoids, including medicinal cannabis and pharmaceu

132 howing that the CB(1) receptor underlies the cannabinoid-induced alterations.

133 (FUB), a recently emerged illicit synthetic cannabinoid infused in street drugs that have been assoc

134 eed for further detailed characterisation of cannabinoid inheritance to facilitate metabolic engineer

135 uces aversive effects that might explain why cannabinoid is not rewarding in rodents and might also a

136 However, CBD, like all natural cannabinoids, is a controlled substance in most countrie

137 rticle will provide information on synthetic cannabinoids, LAARs, and coagulopathic manifestations ar

138 The synthetic nonpsychoactive cannabinoid lenabasum could provide a safe and effective

139 esting with various national legislations on cannabinoids levels in food products.

140 rom nonspecific interactions with lipophilic cannabinoid ligand.

141 Much like cannabinoid ligands and FAAH inhibitors, PPARgamma agoni

142 em, not only because it is able to recognize cannabinoid ligands but also because of its expression a

143 L-alpha-lysophosphatidylinositol and various cannabinoid ligands, may regulate endocrine function and

144 Accordingly, cannabinoids may be a promising therapy against several

145 ance of developing a better understanding of cannabinoid metabolism.

146 geted analysis was performed on three common cannabinoids, namely, Delta9-tetrahydrocannabinol, canna

147 The lipophilic nature of cannabinoids necessitates mechanism(s) to facilitate the

148 s a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection an

149 ity studies directly examining the effect of cannabinoids on treating mental disorders are needed.

150 three grossamide-type, were found, from the cannabinoids, only cannabidiolic acid was detected.

151 athy caused by brodifacoum-tainted synthetic cannabinoids or "fake weed" highlight the public health

152 inatal cannabinoid exposure (using synthetic cannabinoids or active components of the cannabis plant)

153 ypically used forced injections of synthetic cannabinoids or isolated cannabis constituents that may

154 eria included "glaucoma" AND "marijuana" or "cannabinoid" or "CBD." The top 20 Google search and YouT

155 Monoterpenes, sesquiterpenes, hydrocarbons, cannabinoids, other terpenoids, and fatty acids were con

156 and differential expression of terpenoid and cannabinoid pathway genes between cultivars.

157 These results suggest linkage between cannabinoid pathway loci and highlight the need for furt

158 study (XP-GWAS) was used to enrich for alkyl cannabinoid polymorphic regions.

159 cholesterol reduction significantly inhibits cannabinoid potentiation of glycine-activated currents i

160 dole alkaloids, and cannabigerolic acid, the cannabinoid precursor.

161 The system provides an efficient route to cannabinoid precursors cannabigerolic acid (CBGA) and ca

162 We found that cannabinoids principally affect inhibitory inputs, poten

163 Cannabinoid production for medicinal purposes has renewe

164 om the same category can have very different cannabinoids profiles and levels.

165 nnabinoids and opioids via gelatin, and that cannabinoids provide long-term relief of chronic pain st

166 reduced availability of the cerebral type 1 cannabinoid receptor (CB(1)R) in manifest HD.

167 Cannabinoid receptor (CB)(2) is an immune cell-localized

168 itionally, we found that capsaicin increased cannabinoid receptor (CB2) in the cochlea, which leads t

169 Cannabinoid receptor 1 (CB(1)) is a G-protein-coupled re

170 Although cannabinoid receptor 1 (CB1) antagonists have been shown

171 Structures of the cannabinoid receptor 1 (CB1) in complex with an "ultrapo

172 are expressed in the MHb and MSDB, and that cannabinoid receptor 1 (CB1) is expressed in the MSDB.

173 Cannabinoid receptor 1 (CB1) mediates the functional res

174 -enhancing and analgesic effects through the cannabinoid receptor 1 (CB1), a G protein-coupled recept

175 ycerol (2-AG) is acting as a full agonist of cannabinoid receptor 1 and 2.

176 augmentation of AEA signaling and via direct cannabinoid receptor 1 stimulation with Delta(9)-tetrahy

177 As both neurons and glial cells express cannabinoid receptor 1, genetic vulnerability could infl

178 bis constituent and partial agonist of brain cannabinoid receptor 1.

179 xy-benzo(c) chromen-6-one), a cannabilactone cannabinoid receptor 2 (CB2) agonist, suppresses chemoth

180 rachidonoylglycerol (2-AG) and its receptor, cannabinoid receptor 2 (CB2), play a role in the establi

181 ol (2-AG), and elucidated a hitherto unknown cannabinoid receptor 2 (CB2)-mediated regulatory role of

182 t time, that transient administration of the cannabinoid receptor 2 antagonist AM630 (10 mg/kg) or in

183 Cannabinoid receptor 2 deficiency exacerbates inflammati

184 abinoid reporter system, which monitored the cannabinoid receptor activation, was compared to the qua

185 In Caenorhabditis elegans, the endogenous cannabinoid receptor agonist, 2-arachidonoylglycerol (2-

186 The rapid proliferation of new synthetic cannabinoid receptor agonists (SCRAs) has initiated cons

187 Synthetic cannabinoid receptor agonists (SCRAs), termed "Spice" or

188 Notably, cannabinoid receptor agonists as well as inhibitors of e

189 ed the effects and mechanism(s) of action of cannabinoid receptor agonists, including Delta9-THC, on

190 eport that solubilization of a GPCR, type II cannabinoid receptor CB(2), in a Facade detergent enable

191 activity of HER2: heteromerization with the cannabinoid receptor CB(2)R.

192 Cannabinoid receptor CB2 (CB2(-/-)) mice were used as a

193 The cannabinoid receptor CB2 is predominately expressed in t

194 t, upon simultaneous ex-pression of GDE3 and cannabinoid receptor CB2, 2-acyl LPI evoked the same sig

195 he present study demonstrates that mammalian cannabinoid receptor ligands activate a conserved cannab

196 The cannabinoid receptor subtype 2 (CB2R) represents an inte

197 itor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB(2)R) agonist and inv

198 Experiments with cannabinoid receptor type 1 (CB(1))/MGL double-KO mice r

199 - or heterooligomerization between the GPCRs cannabinoid receptor type 1 (CB(1)R) and 5-hydroxytrypta

200 9-THC in endotoxemic mice were reversed by a cannabinoid receptor type 1 (CB(1)R) inverse agonist (SR

201 duced neuronal maturation, downregulation of cannabinoid receptor type 1 (CB1) receptors, and impaire

202 ge, contains among the highest expression of cannabinoid receptor type 1 (CB1r) in the brain.

203 preclinical models, peripherally restricted cannabinoid receptor type 1 (CB1R) inhibitors, which are

204 ness of purposeful movements was reverted by cannabinoid receptor type 1 (CB1r) manipulations directl

205 Cannabinoid receptor type 1 (CB1R) plays a critical role

206 ent report, we aimed to further evaluate the cannabinoid receptor type 1 (CB1R)-mediated mechanisms i

207 her putative Delta9-THC receptors, including cannabinoid receptor type 2, TRPV1, GPR18, GPR55, and GP

208 lucose-feedback sensor) and CNR2 (encoding a cannabinoid receptor) as central effectors of B-lymphoid

209 tein-coupled receptor (GPR) 55 is a putative cannabinoid receptor, and l-alpha-lysophosphatidylinosit

210 19-null animals by the expression of a human cannabinoid receptor, CB1, highlighting the orthology of

211 s a transient window when the dominant brain cannabinoid receptor, CB1R, is expressed on afferent ter

212 port agonist-bound cryo-EM structures of the cannabinoid receptor, CB2, in complex with Gi.

213 e endocannabinoids and their target, the CB1 cannabinoid receptor, in the adaptation of the brain to

214 ing the allosteric binding site on the CB(1) cannabinoid receptor, in which a CF(3) group successfull

215 oid signaling system mediated by a canonical cannabinoid receptor, NPR-19, with orthology to human CB

216 at absorption, and feeding behavior in CB(1) cannabinoid receptor-deficient mice.

217 verses the stress-induced anxiety state in a cannabinoid receptor-dependent manner.

218 Here, we investigated structural changes in cannabinoid-receptor 1 (CB(1))-mediated long-term depres

219 This was replicated by inhibition of cannabinoid receptors (CB(1)R), suggesting a role for en

220 s are mediated through at least two distinct cannabinoid receptors (CB), CB1 and CB2.

221 n the brain, endocannabinoids act via Type 1-cannabinoid receptors (CB1) to modulate synaptic transmi

222 The direct activation of cannabinoid receptors (CBRs) results in several benefici

223 te the effects of blocking TRPV1 or specific cannabinoid receptors 1 (CB1r) and 2 (CB2r) on periodont

224 NADA is also an agonist of cannabinoid receptors 1 and 2.

225 Cannabinoid receptors are distributed in multiple tissue

226 ugh it shares low sequence homology with the cannabinoid receptors CB(1)R and CB(2)R, a growing body

227 l processes mainly through the activation of cannabinoid receptors CB1 and CB2.

228 Mice deficient in cannabinoid receptors, CB1 and CB2, show compromised PDZ

229 ral precision of signaling at neuronal CB(1) cannabinoid receptors, chiefly deregulating Stat3-depend

230 A-derived endocannabinoids desensitize CB(1) cannabinoid receptors, thus inducing epigenetic repressi

231 Cannabinoid receptors, which mediate the actions of cann

232 erate through cell surface G-protein-coupled cannabinoid receptors.

233 be high affinity ligands for the CB1 and CB2 cannabinoid receptors.

234 odels via 2-AG-dependent activation of CB(1) cannabinoid receptors.

235 early developmental stress and is dense with cannabinoid receptors.

236 The levels of cannabinoids recovered in the intestinal lymphatic syste

237 Our data suggest that cannabinoid-related motor effects are associated with un

238 ata (SNr) and suggesting a mechanism for the cannabinoid-related slowness of movements.

239 confirmed by behavioral experiments in which cannabinoid-related slowness of purposeful movements was

240 on between both methods, indicating that the cannabinoid reporter assay can be used for an estimation

241 The cannabinoid reporter assay correctly classified the vast

242 Additionally, the outcome of the cannabinoid reporter assay was compared to the gold stan

243 The outcome of the cell-based cannabinoid reporter system, which monitored the cannabi

244 was designed for the detection of synthetic cannabinoid (SC).

245 AS and CBDAS genotypes were scored and alkyl cannabinoid segregation analysed in 210 F(2) progeny der

246 However, discrete alkyl cannabinoid segregation patterns consistent with digenic

247 Animal models involving traditional cannabinoid self-administration approaches have been not

248 Functional assays in mouse show cannabinoid sensitivity changes and Cnrip1 has recently

249 odents exposed to repeated administration of cannabinoids show persistent microstructural changes in

250 Cannabinoids show promise in the management of pain, but

251 atterns for expression of genes relevant for cannabinoid signaling (from Allen Human Brain Atlas post

252 tractable, mammalian predictive model, where cannabinoid signaling at the molecular/neuronal levels c

253 etically tractable, whole-animal model where cannabinoid signaling at the molecular/neuronal levels c

254 /ion channels whose overall contributions to cannabinoid signaling have yet to be fully assessed.

255 focused on assessing CB(1)/CB(2)-independent cannabinoid signaling in a genetically tractable, whole-

256 g both CB(1)/CB(2)-dependent and independent cannabinoid signaling pathways in a genetically tractabl

257 binoid receptor ligands activate a conserved cannabinoid signaling system in C. elegans and also modu

258 Caenorhabditis elegans contains a cannabinoid signaling system mediated by a canonical can

259 (PPARs) have been identified as part of the cannabinoid signaling system: both phytocannabinoids and

260 tially physiologically restricted endogenous cannabinoid signaling, may be more vulnerable to the eff

261 the complexities of CB(1)/CB(2)-independent cannabinoid signaling, the role of TRP channels in the m

262 In contrast, anti-inflammatory cannabinoids such as cannabidiol or delta-9-tetrahydroca

263 ase activity and the genes for corresponding cannabinoid synthases(7,8).

264 d the contributions and interactions between cannabinoid synthesis pathway loci.

265 hemotypically extreme pools revealed a known cannabinoid synthesis pathway locus as well as a series

266 NPSs including synthetic opioids, synthetic cannabinoids, synthetic cathinones, and piperazines in t

267 0 NPS residues (synthetic opioids, synthetic cannabinoids, synthetic cathinones, piperazines, indole,

268 ignals.SIGNIFICANCE STATEMENT The endogenous cannabinoid system plays diverse roles in brain developm

269 cts mapped onto biomarkers of the endogenous cannabinoid system providing insight into possible mecha

270 However, the contribution of the cannabinoid system to antihyperalgesia against inflammat

271 cture-based discovery of drugs targeting the cannabinoid system.

272 Our previous studies have shown that cannabinoids target a serine residue at position 296 in

273 These results highlighted the importance of cannabinoids testing of food products in view of the cur

274 for the production of natural and unnatural cannabinoids that will allow for more rigorous study of

275 Some cannabinoids, the hallmark constituents of Cannabis, and

276 by mothers during lactation transfers active cannabinoids to the developing offspring during this cri

277 gs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and prevent

278 To investigate the role of the cannabinoid type 1 receptor (CB1) in the formation of se

279 that cocaine-memory reconsolidation requires cannabinoid type 1 receptor (CB1R) signaling based on th

280 Our findings indicate that cannabinoid type 1 receptor (CB1R) signaling is critical

281 e pre-phase of arthritis using butyrate or a cannabinoid type 1 receptor agonist inhibits the develop

282 and a selectivity factor of nearly 700 over cannabinoid type 1 receptors, target compound 3 exhibite

283 slightly better inverse agonist activity at cannabinoid type 1 receptors.

284 The cannabinoid type 2 (CB2) receptor has emerged as a valua

285 Pharmacological modulation of cannabinoid type 2 receptor (CB(2)R) holds promise for t

286 Despite the broad implications of the cannabinoid type 2 receptor (CB2) in neuroinflammatory p

287 ndocannabinoid system, and in particular the cannabinoid type 2 receptor (CB2R), raised the interest

288 Cannabinoid type one receptor (CB1R) is only stably surf

289 aptic responses by activation of presynaptic cannabinoid type-1 (Cb1) receptors is reduced at paralle

290 reviously reported diarylurea derivatives as cannabinoid type-1 receptor (CB(1)) allosteric modulator

291 2R and moderate to good selectivity over the cannabinoid type-1 receptor (CB1R), associated with good

292 ng in male rats via glucocorticoid-dependent cannabinoid type-1 receptor (CB1R)-mediated actions in t

293 Cannabinoid type-1 receptors (Cb1R) are expressed in the

294 late the signal transduction pathways of the cannabinoid type-2 receptor (CB2R) can represent a helpf

295 In this perspective, a set of 18 cannabinoid type-2 receptor (CB2R) ligands was developed

296 creasing evidence suggests that psychoactive cannabinoid use in adolescence enhances the behavioral e

297 try method for the quantification of fifteen cannabinoids was developed and validated for multiple ma

298 nthocyanidins, phytic acid, lignanamides and cannabinoids were determined from the separated phases.

299 are involved in the tetrad assay induced by cannabinoids which had been associated with CB1R agonism

300 with or without preexposure to the synthetic cannabinoid WIN 55,212-2 (WIN).